Figure 3From: FGFR1 is amplified during the progression of in situto invasive breast carcinomaGene amplification status in invasive and ductal carcinoma in situ components of the same tumors. (A) HER2, (B) C-MYC, (C) CCND1 and(D) FGFR1 amplification status in the invasive and ductal carcinoma in situ (DCIS) components agree in most cases. Discordant cases are found in 1.0% for HER2, 4.0% for C-MYC, 2.0% for CCND1 and 3.1% for FGFR1 in combined tissue microarray and whole-section examination.Back to article page